NCT05223036 2026-03-18
Testing Obeticholic Acid for Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
10 trialsNCT05419011 2026-03-18
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06557733 2026-03-18
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT04767984 2026-01-21
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
Northwestern University
Phase 2 Active not recruiting
NCT04729322 2025-12-23
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06730100 2025-10-06
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06425133 2024-12-24
CARE
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT05518032 2024-09-26
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT00390364 2014-10-08
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00513266 2009-08-07
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown